Corrigendum to “In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation” [Biochem. Pharmacol. 123(2017)85–96]

Eitemau Tebyg

• In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation
  gan: Sager, Jennifer E., et al.
  Cyhoeddwyd: (2016)
• Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions
  gan: Huang, Weize, et al.
  Cyhoeddwyd: (2017)
• Fluoxetine and norfluoxetine mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19 and CYP3A4
  gan: Sager, Jennifer E, et al.
  Cyhoeddwyd: (2014)
• Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4′-OH-bupropion in vitro
  gan: Sager, Jennifer E., et al.
  Cyhoeddwyd: (2016)
• Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model
  gan: Xue, Caifu, et al.
  Cyhoeddwyd: (2017)